Atlas Trials

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

Clinical trial NCT02233504 · COMPLETED

Trial details

NCT number
NCT02233504
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
High Risk MDS or AML Patients
Start date
2014-08-01
Primary completion
2017-10-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.